Earnings Call · Q2 FY2024·2024-08-02

Q2 24EPS +12.09%·Rev n/aQ1 24EPS +13.27%·Rev n/aQ4 23EPS -3.09%·Rev n/aQ3 23EPS +8.75%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Neil Gallagher — Chief Medical Officer

Steve Closter — Chief Commercial Officer

Keith Goldan — Chief Financial Officer

−4.4%1d on move date−2.5% vs SPY3d−9.5%5d−9.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access